Literature DB >> 23048034

Roles of ataxin-2 in pathological cascades mediated by TAR DNA-binding protein 43 (TDP-43) and Fused in Sarcoma (FUS).

Yoshihiro Nihei1, Daisuke Ito, Norihiro Suzuki.   

Abstract

The RNA-binding proteins TDP-43 and Fused in Sarcoma (FUS) play central roles in neurodegeneration associated with amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Both proteins are components of messenger ribonucleoprotein (mRNP) granules and show cytoplasmic mislocalization in affected tissues. Recently, ataxin-2 was identified as a potent modifier of TDP-43 toxicity in an RNA-dependent manner. This study investigated to clarify how ataxin-2 modifies the TDP-43 and FUS pathological pathway. The expression of cytoplasmic TDP-43, the 35-kDa C-terminal fragment (TDP-p35f), and mutant FUS recruited ataxin-2 to mRNP granules, whereas increased ataxin-2 inhibited the mRNP granule formation of the 35-kDa C-terminal fragment and mutant FUS. A subcellular compartment analysis showed that the overexpressed ataxin-2 increased the cytoplasmic concentrations of both proteins, whereas it decreased their nuclear distributions. These data indicate that increased ataxin-2 impairs the assembly of TDP-43 and FUS into mRNP granules, leading to an aberrant distribution of RNA-binding proteins. Consequently, these sequences may exacerbate the impairment of the RNA-quality control system mediated by amyotrophic lateral sclerosis/frontotemporal lobar degeneration-associated RNA-binding proteins, which forms the core of the degenerative cascade.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23048034      PMCID: PMC3510829          DOI: 10.1074/jbc.M112.398099

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Global impairment of the ubiquitin-proteasome system by nuclear or cytoplasmic protein aggregates precedes inclusion body formation.

Authors:  Eric J Bennett; Neil F Bence; Rajadas Jayakumar; Ron R Kopito
Journal:  Mol Cell       Date:  2005-02-04       Impact factor: 17.970

Review 2.  Mammalian stress granules and processing bodies.

Authors:  Nancy Kedersha; Paul Anderson
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

3.  Ataxin-2 and its Drosophila homolog, ATX2, physically assemble with polyribosomes.

Authors:  Terrence F Satterfield; Leo J Pallanck
Journal:  Hum Mol Genet       Date:  2006-07-11       Impact factor: 6.150

4.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

5.  Molecular pathogenesis of seipin/BSCL2-related motor neuron diseases.

Authors:  Daisuke Ito; Norihiro Suzuki
Journal:  Ann Neurol       Date:  2007-03       Impact factor: 10.422

6.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Kenji Ikeda; Takashi Nonaka; Hiroshi Mori; David Mann; Kuniaki Tsuchiya; Mari Yoshida; Yoshio Hashizume; Tatsuro Oda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-30       Impact factor: 3.575

7.  Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.

Authors:  I A Klement; P J Skinner; M D Kaytor; H Yi; S M Hersch; H B Clark; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

8.  Ataxin-2 interacts with the DEAD/H-box RNA helicase DDX6 and interferes with P-bodies and stress granules.

Authors:  Ute Nonhoff; Markus Ralser; Franziska Welzel; Ilaria Piccini; Daniela Balzereit; Marie-Laure Yaspo; Hans Lehrach; Sylvia Krobitsch
Journal:  Mol Biol Cell       Date:  2007-02-07       Impact factor: 4.138

9.  Stress granules and processing bodies are dynamically linked sites of mRNP remodeling.

Authors:  Nancy Kedersha; Georg Stoecklin; Maranatha Ayodele; Patrick Yacono; Jens Lykke-Andersen; Marvin J Fritzler; Donalyn Scheuner; Randal J Kaufman; David E Golan; Paul Anderson
Journal:  J Cell Biol       Date:  2005-06-20       Impact factor: 10.539

10.  TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis.

Authors:  Jemeen Sreedharan; Ian P Blair; Vineeta B Tripathi; Xun Hu; Caroline Vance; Boris Rogelj; Steven Ackerley; Jennifer C Durnall; Kelly L Williams; Emanuele Buratti; Francisco Baralle; Jacqueline de Belleroche; J Douglas Mitchell; P Nigel Leigh; Ammar Al-Chalabi; Christopher C Miller; Garth Nicholson; Christopher E Shaw
Journal:  Science       Date:  2008-02-28       Impact factor: 47.728

View more
  14 in total

1.  A case of amyotrophic lateral sclerosis with intermediate ATXN-1 CAG repeat expansion in a large family with spinocerebellar ataxia type 1.

Authors:  Rossella Spataro; Vincenzo La Bella
Journal:  J Neurol       Date:  2014-06-11       Impact factor: 4.849

2.  PTK2/FAK regulates UPS impairment via SQSTM1/p62 phosphorylation in TARDBP/TDP-43 proteinopathies.

Authors:  Shinrye Lee; Yu-Mi Jeon; Sun Joo Cha; Seyeon Kim; Younghwi Kwon; Myungjin Jo; You-Na Jang; Seongsoo Lee; Jaekwang Kim; Sang Ryong Kim; Kea Joo Lee; Sung Bae Lee; Kiyoung Kim; Hyung-Jun Kim
Journal:  Autophagy       Date:  2019-11-05       Impact factor: 16.016

Review 3.  Disruption of RNA Metabolism in Neurological Diseases and Emerging Therapeutic Interventions.

Authors:  Julia K Nussbacher; Ricardos Tabet; Gene W Yeo; Clotilde Lagier-Tourenne
Journal:  Neuron       Date:  2019-04-17       Impact factor: 17.173

Review 4.  TDP43 ribonucleoprotein granules: physiologic function to pathologic aggregates.

Authors:  Giulia Ada Corbet; Joshua R Wheeler; Roy Parker; Kaitlin Weskamp
Journal:  RNA Biol       Date:  2021-08-19       Impact factor: 4.766

Review 5.  Antisense Oligonucleotides for the Study and Treatment of ALS.

Authors:  Benjamin D Boros; Kathleen M Schoch; Collin J Kreple; Timothy M Miller
Journal:  Neurotherapeutics       Date:  2022-06-02       Impact factor: 6.088

Review 6.  Pathomechanisms of TDP-43 in neurodegeneration.

Authors:  Ju Gao; Luwen Wang; Mikayla L Huntley; George Perry; Xinglong Wang
Journal:  J Neurochem       Date:  2018-02-27       Impact factor: 5.372

Review 7.  Examining the relationship between astrocyte dysfunction and neurodegeneration in ALS using hiPSCs.

Authors:  Madeline Halpern; Kristen J Brennand; James Gregory
Journal:  Neurobiol Dis       Date:  2019-08-02       Impact factor: 5.996

Review 8.  The roles of intrinsic disorder-based liquid-liquid phase transitions in the "Dr. Jekyll-Mr. Hyde" behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Vladimir N Uversky
Journal:  Autophagy       Date:  2017-12-17       Impact factor: 16.016

Review 9.  Calcium dysregulation links ALS defective proteins and motor neuron selective vulnerability.

Authors:  Sónia S Leal; Cláudio M Gomes
Journal:  Front Cell Neurosci       Date:  2015-06-16       Impact factor: 5.505

Review 10.  Protein aggregation in amyotrophic lateral sclerosis.

Authors:  Anna M Blokhuis; Ewout J N Groen; Max Koppers; Leonard H van den Berg; R Jeroen Pasterkamp
Journal:  Acta Neuropathol       Date:  2013-05-15       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.